ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) saw its shares shoot up Monday. The San Francisco-based clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to .
ORIC Pharmaceuticals (ORIC) Prices 12.5M Share Offering at $10/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock […]
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CEO Jacob Chacko sold 14,539 shares of ORIC Pharmaceuticals stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $8.58, for a total value of $124,744.62. Following the completion of the sale, the chief executive officer now directly owns 808,544 […]
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CEO Jacob Chacko sold 14,539 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $8.58, for a total transaction of $124,744.62. Following the completion of the transaction, the chief executive officer now owns 808,544 […]